(Press-News.org) The MAF protein interacts with the estrogen receptor, alters its function, and promotes the spread of cancer.
The KDM1A enzyme plays a fundamental role in the epigenetic remodelling that facilitates the function of pro-metastatic genes.
The work carried out in Dr. Roger Gomis Lab at IRB Barcelona has been published in the journal Nature Cell Biology.
Barcelona, 9 November 2023 – Breast cancer is the most common form of cancer among women, with more than 2 million new cases diagnosed each year. In cases where the tumour remains localised in the breast, survival rates are remarkably high, at around 90%. However, the spread of cancer cells beyond breast tissue and the formation of metastases in other organs dramatically worsens the prognosis and poses significant challenges. Previous research has already linked the MAF protein to an increased risk of developing metastasis, but the reasons for this connection remained unclear.
A team from IRB Barcelona led by ICREA researcher Dr. Roger Gomis has revealed the mechanism by which the MAF protein increases the risk of metastasis in breast cancer patients. This finding is a crucial step in understanding the molecular basis of metastasis and has relevant clinical implications for treatment.
The research team has detailed in the journal Nature Cell Biology how the MAF protein interacts with the estrogen receptor, a key element in the development of breast cancer, modifying its structure. This interaction leads to DNA restructuring, which allows the activation of genes that favour metastasis, particularly in response to estrogen. These findings imply that patients with high levels of MAF protein have a greater risk of developing metastasis.
This study opens up the possibility of preventing metastasis by impeding the activation of pro-metastatic through the inhibition of the KDM1A molecule, which is responsible for DNA restructuring. This offers new perspectives in the treatment of breast cancer. The study was carried out in cultured cells and animal models of the disease, and it was validated in patient samples.
The research has been supported by the "la Caixa" Foundation through the 2018 Health Call. The project has also received funding by the Spanish Association Against Cancer, the FERO Foundation, the BBVA Foundation and the Spanish Ministry of Science and Innovation. The project has also been supported by Mrs. Carme Segura Capellades, who donates generously to cancer research at IRB Barcelona.
Crucial discovery for young and premenopausal patients
Previous studies by the same laboratory had already established a connection between increased MAF protein levels and resistance to "bisphosphonate" treatment used to prevent breast cancer metastasis to bone.
The detection of high levels of MAF can therefore predict the risk of metastasis, as well as distinguish between breast cancer patients who may benefit from bisphosphonate treatment from those for whom this treatment is inappropriate. This information is particularly crucial for young patients. Treatments aimed at the site of bone metastasis can, in some cases, divert metastasis to other organs, which has a negative impact on the overall survival of patients.
"This finding is a critical step in understanding how breast cancer spreads and opens up new therapeutic options for the 20% of patients who cannot benefit from bisphosphonate treatment," explains Dr. Gomis, head of the Growth Control and Cancer Metastasis laboratory at IRB Barcelona and also a group leader at the Cancer CIBER (CIBERONC).
The MAF Test: a diagnostic tool that is now available
The research carried out in Dr. Gomis' lab has led to the development of the MAF Test, a predictive tool available for breast cancer patients. This diagnostic test has been developed by Inbiomotion, a spin-off from IRB Barcelona and ICREA founded in 2011, and is available in Spain through PALEX Medical.
The MAF Test allows the identification of breast cancer patients with a greater risk of developing metastasis and facilitates informed decisions by oncologists about the most appropriate treatment for each case.
A drug currently in clinical trials could benefit these patients
An inhibitor of the element that researchers have identified as key in the metastatic drift of breast cancer, namely the KDM1A protein, has already been identified and is currently in clinical trials to validate its effectiveness and safety. This inhibitor and related trials are independent of the findings published today. However, if this potential drug is confirmed to be effective, it could offer significant benefits for patients with elevated MAF levels by helping to prevent the development of metastases.
The first authors of the study are Dr. Alicia Llorente, who started this work during her doctoral studies, Dr. Teresa Blasco, who also signs as responsible for the publication, together with Dr. Gomis and Irene Espuny. All three work in Dr. Gomis' laboratory. The research was carried out in collaboration with the laboratories headed by Dr. Luciano Di Croce, at the Center for Genomic Regulation, Dr. Alexandra Avgustinova at IRB Barcelona and the Institut de Recerca Sant Joan de Deu, and Dr. Ingunn Holen, at the University of Sheffield. The study also involved the groups led by Dr. Antoni Riera and Dr. Freddy Monteiro (both at IRB Barcelona), and Dr. Mariona Graupera, at the Josep Carreras Leukemia Research Institute.
END
Researchers decipher the mechanism by which the MAF protein promotes breast cancer metastasis
2023-11-09
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
New research: Fivefold increase in the melting of Greenland's glaciers over the last 20 years
2023-11-09
New research: Fivefold increase in the melting of Greenland's glaciers over the last 20 years
In the largest survey of its kind ever conducted, using both satellite imagery and old aerial photos from the Danish National Archives, researchers from the University of Copenhagen firmly establish that Greenland’s glaciers are melting at an unprecedented pace. Melting has increased fivefold in the past 20 years. The study eliminates any lingering doubts about the impact of climate change on Greenland's more than 20,000 glaciers.
Based on the most comprehensive monitoring ...
Drug screen points toward novel diabetes treatments
2023-11-09
A drug currently in clinical trials as a cancer therapy can also stimulate pancreatic beta cells to secrete insulin, revealing a previously unknown mechanism for insulin regulation in type 2 diabetes, according to a new study by Weill Cornell Medicine investigators. The preclinical discovery, reported Nov. 9 in Nature Chemical Biology, provides a new chemical tool for probing the biology of diabetes, and could point the way toward better treatments for the disease.
“We have known about insulin for a century, but when it comes to the major mechanisms controlling insulin secretion, there ...
Team creates synthetic enzymes to unravel molecular mysteries
2023-11-09
A University of Texas at Dallas bioengineer has developed synthetic enzymes that can control the behavior of the signaling protein Vg1, which plays a key role in the development of muscle, bone and blood in vertebrate embryos.
The team of researchers is using a new approach, called the Synthetic Processing (SynPro) system, in zebrafish to study how Vg1 is formed. By learning the molecular rules of signal formation in a developing animal, researchers aim to engineer mechanisms — such as giving cells new instructions — that could play a role in treating or preventing disease.
Dr. P.C. Dave P. Dingal, assistant professor of bioengineering in the Erik Jonsson ...
Finding your niche: A synthetic cancer stem cell microenvironment
2023-11-09
Researchers from Tokyo Medical and Dental University (TMDU) report the construction of a synthetic polymer biomaterial that successfully recapitulates the pancreatic adenocarcinoma microenvironment and could be used to identify novel treatment targets
Tokyo, Japan – One of the biggest challenges in biomedical research is finding a way to capture the complexity of the human body in laboratory-based techniques, to enable them to be investigated accurately. Now, researchers from Japan report an approach for precisely imitating a key feature of aggressive cancers in the laboratory.
In a study published recently in Inflammation and Regeneration, researchers from Tokyo Medical and ...
Vigorous exercise, rigorous science: What scientists learned from firefighters in training
2023-11-09
The 11 young firefighters went through a rigorous training exercise, carrying up to 40 pounds of gear over hilly terrain during a 45-minute training exercise in the California sun. Gloves, helmets, flashlights, goggles, and more weighted them down as they sprinted through the countryside wearing fire-resistant clothing to show they were ready to serve as wildland firefighters.
When the training was over, they immediately went to the medical tent—not to rest and recover but to give samples of their blood, ...
Study reveals the structure of brain waves associated with memory consolidation
2023-11-09
The reactivation of patterns of neuronal activity based on experience is crucial for learning and memory, but these patterns and the associated brain waves vary widely and are difficult to classify. Such events, dubbed ripples, are characteristic of the hippocampus, a brain region responsible for memory. Until now, the most common way to study ripples was using frequency analysis, but a project led by the Spanish National Research Council (CSIC) has proposed a new classification strategy.
Using data science tools, a research group from the Instituto Cajal (IC-CSIC) headed by Liset M. de la Prida has managed to figure out the temporal structure of hippocampal ripples. The scientists ...
Reducing vitamin B5 slows breast cancer growth in mice
2023-11-09
Francis Crick Institute press release
Under strict embargo: 16:00hrs GMT Thursday 9 November 2023
Peer reviewed
Experimental study
People and animals
Reducing vitamin B5 slows breast cancer growth in mice
A group of researchers led by the Francis Crick Institute, working with the National Physical Laboratory (NPL) and Imperial College London, have discovered that breast cancer cells expressing a cancer-driving gene heavily rely on vitamin B5 to grow and survive. The researchers are part of Cancer Grand Challenges team Rosetta, funded by Cancer Research UK.
In their research published today in Nature Metabolism, the team studied the metabolic effects of one of the major cancer-driving ...
Smell and taste function 3 years after mild COVID-19
2023-11-09
About The Study: There was a favorable evolution in smell and taste function throughout the observation period of this study, with taste dysfunction showing lower frequency and faster recovery compared with smell dysfunction in this analysis that included 88 cases and 88 controls. Recovery from smell dysfunction continued over the 3-year study period. At the 3-year study endpoint, smell dysfunction was comparable between both groups. Patients with post–COVID-19 condition exhibiting chemosensory alterations should be reassured that a recovery of smell function appears to continue over three years ...
Assessment of changes in cancer treatment during the first year of the pandemic
2023-11-09
About The Study: In this study including 3.5 million patients diagnosed with cancer, a significant deficit was noted in the number of cancer treatments provided in the first year of the COVID-19 pandemic in the U.S. Data indicated that this deficit in the number of cancer treatments provided was associated with decreases in the number of cancer diagnoses, not changes in treatment strategies.
Authors: Leticia M. Nogueira, Ph.D., M.P.H., of the American Cancer Society in Kennesaw, Georgia, is the corresponding author.
To access ...
Social-behavioral findings can be highly replicable, six-year study by four labs suggests
2023-11-09
Roughly two decades ago, a community-wide reckoning emerged concerning the credibility of published literature in the social-behavioral sciences, especially psychology. Several large scale studies attempted to reproduce previously published findings to no avail or to a much lesser magnitude, sending the credibility of the findings — and future studies in social-behavioral sciences — into question.
A handful of top experts in the field, however, set out to ...